ENTX Stock Overview
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.
Entera Bio Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.19|
|52 Week High||US$5.24|
|52 Week Low||US$1.14|
|1 Month Change||-15.00%|
|3 Month Change||-26.54%|
|1 Year Change||-75.26%|
|3 Year Change||-52.21%|
|5 Year Change||n/a|
|Change since IPO||-81.05%|
Recent News & Updates
Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Entera Bio press release (NASDAQ:ENTX): 1H GAAP EPS of -$0.24. Revenue of $0.11M (-59.3% Y/Y). Shares +3.68% PM
|ENTX||US Biotechs||US Market|
Return vs Industry: ENTX underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: ENTX underperformed the US Market which returned -23.1% over the past year.
|ENTX Average Weekly Movement||11.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ENTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ENTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Entera Bio Ltd. Fundamentals Summary
|ENTX fundamental statistics|
Is ENTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENTX income statement (TTM)|
|Cost of Revenue||US$288.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.50|
|Net Profit Margin||-3,425.18%|
How did ENTX perform over the long term?See historical performance and comparison